ecrin-mdr-crcClinical2022IPD Sharing (as of September 2022): NoMetastatic Colorectal CancerColorectal NeoplasmsMetastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/272670412CapecitabineTislelizumabECRIN MDRNot yet recruitingfalseMaintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal CancerSurgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new clinical setting known as mCRC with no evidence of disease (NED). However, these patients have a high risk of developing persistent cancer. This study aimed to investigate the efficacy and safety of Tislelizumab combined with capecitabine as a maintenance treatment for patients with mCRC-NED.2022-12-152726704NCT05360277